The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4x Discry Hdgs Regulatory News (C4XD)

Share Price Information for C4x Discry Hdgs (C4XD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.00
Bid: 10.30
Ask: 10.80
Change: 2.575 (27.32%)
Spread: 0.50 (4.854%)
Open: 9.40
High: 12.00
Low: 9.20
Prev. Close: 12.00
C4XD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

5 Apr 2017 12:24

RNS Number : 6815B
C4X Discovery Holdings PLC
05 April 2017
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

C4X DISCOVERY HOLDINGS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

ü

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

HARGREAVE HALE LIMITED

4. Full name of shareholder(s)  (if different from 3.):iv

DISCRETIONARY CLIENTS

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

03 APRIL 2017

6. Date on which issuer notified:

04 APRIL 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Indirect

Direct xi

Indirect xii

Direct

Indirect

GB00BQQ2RV18

0

0

2,441,000

2,441,000

5.3491%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,441,000

5.3491%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

All of these shares are held for unit trusts operated by Marlborough Fund Managers Ltd, for whom Hargreave Hale Ltd manages the investments on a discretionary basis.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

The change in the percentage of shares held is due entirely to participation in the placing by C4X Discovery Holdings Plc, the shares from which were admitted to AIM on 03/04/2017.

14. Contact name:

David Clueit,

Hargreave Hale Ltd

15. Contact telephone number:

01253 754739

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLOKPDBDBKDBQK
Date   Source Headline
28th Jun 20225:46 pmRNSAIM Rule 17 Schedule 2(g) Update
28th Apr 20227:00 amRNSHalf Year Results
19th Apr 20227:00 amRNSNotice of Results
28th Feb 20225:30 pmRNSExercise of Options, Issue of Equity and TVR
3rd Feb 20227:00 amRNSGrant of Options and Directors Dealing
1st Feb 20227:00 amRNSBlock listing Return
1st Feb 20227:00 amRNSBhavna Hunjan Appointed as Chief Business Officer
24th Jan 20224:09 pmRNSHolding(s) in Company
18th Jan 20223:07 pmRNSResult of AGM
14th Jan 20223:20 pmRNSHoldings in Company
21st Dec 20217:00 amRNSAppointment of Dr Cathy Tralau-Stewart as CSO
15th Dec 20217:00 amRNSAnnual Report and Notice of AGM
13th Dec 20216:11 pmRNSTotal Voting Rights
13th Dec 20217:00 amRNSFull Year Results
9th Dec 20217:00 amRNSNotice of Results
3rd Dec 202110:34 amRNSClive Dix wins Scrip Lifetime Achievement Award
2nd Dec 20217:01 amRNSClive Dix awarded Honorary Fellowship
2nd Dec 20217:00 amRNSBoard Change
26th Nov 202110:20 amRNSClive Dix wins OBN Special Recognition Award
19th Nov 20217:00 amRNSBoard Change
10th Nov 20215:01 pmRNSHolding(s) in Company
10th Nov 20214:58 pmRNSHolding(s) in Company
8th Nov 20214:33 pmRNSHolding(s) in Company
3rd Aug 20215:14 pmRNSTotal Voting Rights
1st Jul 202111:51 amRNSTotal Voting Rights
27th May 202110:04 amRNSExercise of Options
13th May 20212:49 pmRNSHolding(s) in Company
29th Apr 20217:00 amRNSInterim Results
22nd Apr 20214:40 pmRNSSecond Price Monitoring Extn
22nd Apr 20214:36 pmRNSPrice Monitoring Extension
22nd Apr 202111:31 amRNSNotice of Results
20th Apr 20217:00 amRNSBoard Appointment
12th Apr 20219:05 amRNSSecond Price Monitoring Extn
12th Apr 20219:00 amRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSSanofi Agreement
12th Mar 20217:00 amRNSHolding(s) in Company
11th Mar 20219:33 amRNSHolding(s) in Company
2nd Mar 202111:56 amRNSHolding(s) in Company
1st Mar 20214:26 pmRNSHolding(s) in Company
24th Feb 20212:03 pmRNSHolding(s) in Company
25th Jan 20219:37 amRNSHolding(s) in Company
19th Jan 20212:28 pmRNSResult of AGM
23rd Dec 20204:40 pmRNSSecond Price Monitoring Extn
23rd Dec 20204:36 pmRNSPrice Monitoring Extension
18th Dec 20209:12 amRNSPublication of 2020 Annual Report
17th Dec 20204:10 pmRNSHolding(s) in Company
14th Dec 20205:14 pmRNSGrant of options and Directors Dealing
10th Dec 20207:00 amRNSFull Year Results
9th Dec 20201:54 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSClive Dix named Interim Chair of Vaccine Taskforce

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.